Animal models of osteosarcoma

References

• McKenna RJ, Schwinn CP, Soong KY, Higinbotham NL. Osteogenic sarcoma arising in Paget’s disease. Cancer17, 42–66 (1964).
   PubMedGoogle Scholar
• Sissons HA. The WHO classification of bone tumors. Recent Results Cancer Res. (54), 104–108 (1976).
   PubMedGoogle Scholar
• Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am. J. Clin. Pathol.125(4), 555–581 (2006).
   PubMed Web of Science ®Google Scholar
• Goorin AM, Abelson HT, Frei E 3rd. Osteosarcoma: fifteen years later. N. Engl. J. Med.313(26), 1637–1643 (1985).
   PubMed Web of Science ®Google Scholar
• Fine G, Stout AP. Osteogenic sarcoma of the extraskeletal soft tissues. Cancer9(5), 1027–1043 (1956).
   PubMed Web of Science ®Google Scholar
• Kauffman SL, Stout AP. Extraskeletal osteogenic sarcomas and chondrosarcomas in children. Cancer16, 432–439 (1963).
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat. Res.152, 15–32 (2010).
   Google Scholar
• Longhi A, Pasini A, Cicognani A et al. Height as a risk factor for osteosarcoma. J. Pediatr. Hematol. Oncol.27(6), 314–318 (2005).
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat. Res.152, 3–13 (2010).
   Google Scholar
• Tallroth K, Makai F, Musumeci R. Lymphography in bone and soft tissue sarcomas. Experiences from three institutions. Tumori66(6), 721–728 (1980).
   PubMedGoogle Scholar
• Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin. Cancer Res.11(13), 4666–4673 (2005).
   PubMed Web of Science ®Google Scholar
• Makai F, Belan A, Malek P. Lymphatic metastases of bone tumors. Lymphology4(3), 109–115 (1971).
   PubMedGoogle Scholar
• Bacci G, Picci P, Ferrari S et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute. Cancer Treat. Res.62, 299–308 (1993).
   PubMedGoogle Scholar
• Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol.19(4), 341–346 (2007).
   PubMed Web of Science ®Google Scholar
• Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist9(4), 422–441 (2004).
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer115(22), 5339–5348 (2009).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol.23(9), 2004–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Hansen MF. Molecular genetic considerations in osteosarcoma. Clin. Orthop. Relat. Res. (270), 237–246 (1991).
   PubMedGoogle Scholar
• Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250(4985), 1233–1238 (1990).
   PubMed Web of Science ®Google Scholar
• Miller CW, Aslo A, Won A et al. Alterations of the p53, Rband MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol.122(9), 559–565 (1996).
   PubMed Web of Science ®Google Scholar
• Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer75(8), 2186–2195 (1995).
   PubMed Web of Science ®Google Scholar
• Wadayama B, Toguchida J, Shimizu T et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res.54(11), 3042–3048 (1994).
   PubMed Web of Science ®Google Scholar
• Hansen MF, Koufos A, Gallie BL et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc. Natl Acad. Sci. USA82(18), 6216–6220 (1985).
   PubMed Web of Science ®Google Scholar
• Puranam KL, Kennington E, Sait SN et al. Chromosomal localization of the gene encoding the human DNA helicase RECQL and its mouse homologue. Genomics26(3), 595–598 (1995).
   PubMedGoogle Scholar
• Watt PM, Hickson ID. Failure to unwind causes cancer. Genome stability. Curr. Biol.6(3), 265–267 (1996).
   PubMedGoogle Scholar
• Mohaghegh P, Hickson ID. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum. Mol. Genet.10(7), 741–746 (2001).
   PubMedGoogle Scholar
• Wang LL, Gannavarapu A, Kozinetz CA et al. Association between osteosarcoma and deleterious mutations in the RECQL4gene in Rothmund–Thomson syndrome. J. Natl Cancer Inst.95(9), 669–674 (2003).
   PubMed Web of Science ®Google Scholar
• Chun R, de Lorimier LP. Update on the biology and management of canine osteosarcoma. Vet. Clin. North Am. Small Anim. Pract.33(3), 491–516 (2003).
   PubMed Web of Science ®Google Scholar
• Hadjipavlou A, Lander P, Srolovitz H, Enker IP. Malignant transformation in Paget disease of bone. Cancer70(12), 2802–2808 (1992).
   PubMed Web of Science ®Google Scholar
• Edeiken J, DePalma AF, Hodes PJ. Paget’s disease: osteitis deformans. Clin. Orthop. Relat. Res.46, 141–153 (1966).
   PubMedGoogle Scholar
• Tucker MA, D’Angio GJ, Boice JD Jr et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med.317(10), 588–593 (1987).
   PubMed Web of Science ®Google Scholar
• Steeves RA, Bataini JP. Neoplasms induced by megavoltage radiation in the head and neck region. Cancer47(7), 1770–1774 (1981).
   PubMedGoogle Scholar
• Gillette SM, Gillette EL, Powers BE, Withrow SJ. Radiation-induced osteosarcoma in dogs after external beam or intraoperative radiation therapy. Cancer Res.50(1), 54–57 (1990).
   PubMedGoogle Scholar
• Berman SD, Calo E, Landman AS et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl Acad. Sci. USA105(33), 11851–11856 (2008).
   PubMed Web of Science ®Google Scholar
• Walkley CR, Qudsi R, Sankaran VG et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev.22(12), 1662–1676 (2008).
   PubMed Web of Science ®Google Scholar
• Cameron MD, Schmidt EE, Kerkvliet N et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res.60(9), 2541–2546 (2000).
   PubMed Web of Science ®Google Scholar
• Koop S, MacDonald IC, Luzzi K et al. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res.55(12), 2520–2523 (1995).
   PubMed Web of Science ®Google Scholar
• McAllister RM, Gardner MB, Greene AE et al. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer27(2), 397–402 (1971).
   PubMedGoogle Scholar
• McAllister RM, Nelson-Rees WA, Peer M et al. Childhood sarcomas and lymphomas. Characterization of new cell lines and search for type-C virus. Cancer36(5), 1804–1814 (1975).
   PubMedGoogle Scholar
• Luu HH, Kang Q, Park JK et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis22(4), 319–329 (2005).
   PubMed Web of Science ®Google Scholar
• Berlin O, Samid D, Donthineni-Rao R et al. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res.53(20), 4890–4895 (1993).
   PubMedGoogle Scholar
• McGary EC, Weber K, Mills L et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res.8(11), 3584–3591 (2002).
   PubMed Web of Science ®Google Scholar
• McGary EC, Heimberger A, Mills L et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.Clin. Cancer Res.9(17), 6560–6566 (2003).
   PubMedGoogle Scholar
• Labrinidis A, Hay S, Liapis V et al. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin. Cancer Res.15(10), 3451–3461 (2009).
   PubMed Web of Science ®Google Scholar
• Jones PA, Rhim JS, Isaacs H Jr, McAllister RM. The relationship between tumorigenicity, growth in agar and fibrinolytic activity in a line of human osteosarcoma cells. Int. J. Cancer16(4), 616–621 (1975).
   PubMed Web of Science ®Google Scholar
• Rhim JS, Putman DL, Arnstein P, Huebner RJ, McAllister RM. Characterization of human cells transformed in vitro by N-methyl-N´-nitro-N-nitrosoguanidine. Int. J. Cancer19(4), 505–510 (1977).
   PubMedGoogle Scholar
• Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin. Orthop. Relat. Res.466(9), 2039–2045 (2008).
   PubMed Web of Science ®Google Scholar
• Rubin EM, Guo Y, Tu K et al. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther.9(3), 731–741 (2010).
   PubMedGoogle Scholar
• Tome Y, Tsuchiya H, Hayashi K et al.In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential. J. Cell. Biochem.108(2), 362–367 (2009).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Zhao M, Yamauchi K et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium.Cell Cycle8(6), 870–875 (2009).
   PubMed Web of Science ®Google Scholar
• Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl Cancer Inst.59(1), 221–226 (1977).
   PubMed Web of Science ®Google Scholar
• Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis17(6), 501–506 (1999).
   PubMed Web of Science ®Google Scholar
• Jia SF, Worth LL, Turan M, Duan Xp XP, Kleinerman ES. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drug13(2), 155–161 (2002).
   Google Scholar
• Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin. Exp. Metastasis23(7–8), 367–380 (2006).
   PubMed Web of Science ®Google Scholar
• Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin. Exp. Metastasis24(2), 93–106 (2007).
   PubMed Web of Science ®Google Scholar
• Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther.14(7), 616–626 (2007).
   PubMed Web of Science ®Google Scholar
• Ek ET, Dass CR, Contreras KG, Choong PF. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J. Orthop. Res.25(12), 1671–1680 (2007).
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther.6(12 Pt 1), 3263–3270 (2007).
   PubMed Web of Science ®Google Scholar
• Dass CR, Contreras KG, Dunstan DE, Choong PF. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials28(19), 3026–3033 (2007).
   PubMed Web of Science ®Google Scholar
• Martin TJ, Ingleton PM, Underwood JC et al. Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature260(5550), 436–438 (1976).
   PubMed Web of Science ®Google Scholar
• Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin. Cancer Res.7(6), 1654–1660 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt J, Strauss GP, Schon A et al. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation39(3), 151–160 (1988).
   PubMedGoogle Scholar
• Khanna C, Prehn J, Yeung C et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis18(3), 261–271 (2000).
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res.65(6), 2406–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Terabe M, Khanna C, Bose S et al. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-β. Cancer Res.66(7), 3869–3875 (2006).
   PubMed Web of Science ®Google Scholar
• Barkan D, Kleinman H, Simmons JL et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res.68(15), 6241–6250 (2008).
   PubMed Web of Science ®Google Scholar
• Merchant MS, Melchionda F, Sinha M et al. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol. Immunother.56(7), 1037–1046 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon N, Koshkina NV, Jia SF et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin.Cancer Res.13(15 Pt 1), 4503–4510 (2007).
   PubMed Web of Science ®Google Scholar
• Leaner VD, Chick JF, Donninger H et al. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am. J. Pathol.174(1), 265–275 (2009).
   PubMedGoogle Scholar
• Hong SH, Briggs J, Newman R et al. Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int. J. Cancer124(9), 2042–2049 (2009).
   PubMedGoogle Scholar
• Kim SY, Lee CH, Midura BV et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis25(3), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Miretti S, Roato I, Taulli R et al. A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS ONE3(3), e1828 (2008).
   Google Scholar
• Asai T, Ueda T, Itoh K et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer76(3), 418–422 (1998).
   PubMed Web of Science ®Google Scholar
• Sottnik JL, Duval DL, Ehrhart EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin. Exp. Metastasis27(3), 151–160 (2010).
   PubMed Web of Science ®Google Scholar
• Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl Acad. Sci. USA85(14), 5166–5170 (1988).
   PubMed Web of Science ®Google Scholar
• Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res.27(1A), 155–164 (2007).
   PubMed Web of Science ®Google Scholar
• Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin. Orthop. Relat. Res. (270), 159–168 (1991).
   PubMedGoogle Scholar
• Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest.18(8), 781–792 (2000).
   PubMed Web of Science ®Google Scholar
• van Leeuwen IS, Cornelisse CJ, Misdorp W et al.P53 gene mutations in osteosarcomas in the dog. Cancer Lett.111(1–2), 173–178 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson AS, Couto CG, Weghorst CM. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis19(1), 213–217 (1998).
   PubMed Web of Science ®Google Scholar
• Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet. Pathol.37(1), 54–61 (2000).
   PubMedGoogle Scholar
• Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet. Pathol.39(3), 372–378 (2002).
   PubMed Web of Science ®Google Scholar
• Ferracini R, Angelini P, Cagliero E et al.MET oncogene aberrant expression in canine osteosarcoma. J. Orthop. Res.18(2), 253–256 (2000).
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kutzke J, Carew J et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin. Exp. Metastasis20(5), 421–430 (2003).
   PubMedGoogle Scholar
• De Maria R, Miretti S, Iussich S et al.MET oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J. Pathol.218(3), 399–408 (2009).
   PubMedGoogle Scholar
• Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med.10(2), 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Paoloni M, Davis S, Lana S et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics10, 625 (2009).
   PubMed Web of Science ®Google Scholar
• Liao AT, McMahon M, London CA. Identification of a novel germline MET mutation in dogs. Anim. Genet.37(3), 248–252 (2006).
   PubMedGoogle Scholar